North China Pharmaceutical Co Ltd (600812) - Total Liabilities
Based on the latest financial reports, North China Pharmaceutical Co Ltd (600812) has total liabilities worth CN¥14.52 Billion CNY (≈ $2.12 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore North China Pharmaceutical Co Ltd (600812) net asset momentum to track the company's year-over-year net asset growth rate.
North China Pharmaceutical Co Ltd - Total Liabilities Trend (1993–2025)
This chart illustrates how North China Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of North China Pharmaceutical Co Ltd to measure how efficiently the company converts operating cash flow to free cash.
North China Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of North China Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
FuelCell Energy Inc
NASDAQ:FCEL
|
USA | $274.87 Million |
|
Borr Drilling Ltd
NYSE:BORR
|
USA | $2.40 Billion |
|
Direcional Engenharia S.A.
SA:DIRR3
|
Brazil | R$9.70 Billion |
|
Shanghai QiFan Cable Co Ltd
SHG:605222
|
China | CN¥10.05 Billion |
|
Deluxe Corporation
NYSE:DLX
|
USA | $1.86 Billion |
|
Wuxi Xinhongye Wire & Cable Co. Ltd. A
SHE:301310
|
China | CN¥3.36 Billion |
|
Hitevision Co Ltd
SHE:002955
|
China | CN¥1.33 Billion |
|
ARB Corporation Ltd
AU:ARB
|
Australia | AU$134.90 Million |
Liability Composition Analysis (1993–2025)
This chart breaks down North China Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 600812 market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.72 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.62 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.68 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how North China Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for North China Pharmaceutical Co Ltd (1993–2025)
The table below shows the annual total liabilities of North China Pharmaceutical Co Ltd from 1993 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥14.51 Billion ≈ $2.12 Billion |
-1.96% |
| 2024-12-31 | CN¥14.80 Billion ≈ $2.17 Billion |
+0.75% |
| 2023-12-31 | CN¥14.69 Billion ≈ $2.15 Billion |
-2.04% |
| 2022-12-31 | CN¥14.99 Billion ≈ $2.19 Billion |
-16.30% |
| 2021-12-31 | CN¥17.91 Billion ≈ $2.62 Billion |
+6.14% |
| 2020-12-31 | CN¥16.88 Billion ≈ $2.47 Billion |
+30.65% |
| 2019-12-31 | CN¥12.92 Billion ≈ $1.89 Billion |
+4.13% |
| 2018-12-31 | CN¥12.40 Billion ≈ $1.82 Billion |
+4.50% |
| 2017-12-31 | CN¥11.87 Billion ≈ $1.74 Billion |
+6.13% |
| 2016-12-31 | CN¥11.18 Billion ≈ $1.64 Billion |
+4.26% |
| 2015-12-31 | CN¥10.73 Billion ≈ $1.57 Billion |
+3.97% |
| 2014-12-31 | CN¥10.32 Billion ≈ $1.51 Billion |
-0.93% |
| 2013-12-31 | CN¥10.41 Billion ≈ $1.52 Billion |
+11.23% |
| 2012-12-31 | CN¥9.36 Billion ≈ $1.37 Billion |
-5.93% |
| 2011-12-31 | CN¥9.95 Billion ≈ $1.46 Billion |
+25.37% |
| 2010-12-31 | CN¥7.94 Billion ≈ $1.16 Billion |
+23.85% |
| 2009-12-31 | CN¥6.41 Billion ≈ $937.99 Million |
+19.43% |
| 2008-12-31 | CN¥5.37 Billion ≈ $785.39 Million |
+2.90% |
| 2007-12-31 | CN¥5.22 Billion ≈ $763.27 Million |
-7.10% |
| 2006-12-31 | CN¥5.61 Billion ≈ $821.62 Million |
+1.22% |
| 2005-12-31 | CN¥5.55 Billion ≈ $811.71 Million |
-5.85% |
| 2004-12-31 | CN¥5.89 Billion ≈ $862.15 Million |
+30.66% |
| 2003-12-31 | CN¥4.51 Billion ≈ $659.85 Million |
+5.08% |
| 2002-12-31 | CN¥4.29 Billion ≈ $627.94 Million |
-7.40% |
| 2001-12-31 | CN¥4.63 Billion ≈ $678.12 Million |
+41.82% |
| 2000-12-31 | CN¥3.27 Billion ≈ $478.15 Million |
+12.65% |
| 1999-12-31 | CN¥2.90 Billion ≈ $424.44 Million |
+44.42% |
| 1998-12-31 | CN¥2.01 Billion ≈ $293.89 Million |
+28.34% |
| 1997-12-31 | CN¥1.56 Billion ≈ $229.00 Million |
+12.93% |
| 1996-12-31 | CN¥1.39 Billion ≈ $202.77 Million |
+34.41% |
| 1995-12-31 | CN¥1.03 Billion ≈ $150.86 Million |
+51.01% |
| 1994-12-31 | CN¥682.69 Million ≈ $99.90 Million |
+63.55% |
| 1993-12-31 | CN¥417.41 Million ≈ $61.08 Million |
-- |
About North China Pharmaceutical Co Ltd
North China Pharmaceutical Company.Ltd engages in the research and development, production, and sales of pharmaceutical products in China and internationally. The company primarily offers anti-infective drugs, biotechnology drugs, cardiovascular cerebrovascular, immunomodulators, and vitamins and health products. It also provides chemical pharmaceuticals; and biological, agricultural, and veterin… Read more